Clik here to view.
Google's parent company Alphabet poaches Eli Lilly CFO; More changes at...
Anat Ashkenazi → It’s been nearly a year since Google’s parent company Alphabet announced that its CFO Ruth Porat would move into the newly created role of president and chief investment officer,...
View ArticleClik here to view.
Biomea’s early-stage diabetes drug put on full clinical hold, stock crashes
Biomea Fusion’s Phase 1/2 covalent menin inhibitor program in diabetes has been placed on full clinical hold due to “possible” drug-related hepatotoxicity. Liver enzyme elevations were flagged in the...
View ArticleClik here to view.
#EASL24: Boehringer Ingelheim, Zealand tout key fibrosis data from mid-stage...
Boehringer Ingelheim officially unveiled fibrosis data from a mid-stage trial of its Zealand Pharma-partnered drug in MASH on Friday, after its liver congress abstract was “unintentionally and...
View ArticleIpsen returns to Marengo Therapeutics for new trispecific deal
Ipsen and Marengo Therapeutics are expanding a deal to include two trispecific antibody assets that tackle so-called cold tumors, which do not typically respond well to immunotherapies. The companies...
View Article#EASL24: Aligos, Arbutus, Atea, Barinthus and Bluejay unveil hepatitis results
At this year’s EASL International Liver Congress, Vir took center stage Wednesday to report early Phase 2 data for its hepatitis D approach, and then saw its stock $VIR jump as much as 15% upon data...
View ArticleNeuroscience company Rapport Therapeutics lists on Nasdaq
Rapport Therapeutics expects to raise $154 million from its initial public offering and a concurrent stock sale to private investors, the company announced Thursday evening. Rapport, a neuroscience...
View ArticleAbbVie and Alphabet's Calico added to Operation Warp Speed for rare diseases
AbbVie and Alphabet’s Calico announced Friday that their potential treatment for the rare neurological disease known as vanishing white matter disease will be part of the FDA’s new Operation Warp Speed...
View ArticleItalian antitrust agency investigates Novartis, Biogen and others over...
Italian antitrust authorities are investigating four companies over alleged collusion to delay the introduction of a new biosimilar to Roche’s blockbuster eye drug Lucentis. The Italian Competition...
View ArticleClik here to view.
FDA greenlights Geron’s imetelstat to treat anemia in certain cancer patients
The FDA approved Geron’s imetelstat to treat certain anemic myelodysplastic syndrome (MDS) patients who are dependent on blood transfusions. The approval comes after the FDA’s Oncologic Drugs Advisory...
View ArticleFederal judge dismisses antitrust claims brought against Bristol Myers by...
A federal judge in New Jersey district court on Thursday dismissed anticompetitive claims brought against Bristol Myers Squibb by a number of insurers over an alleged scheme to delay generic entry for...
View ArticleFDA raises questions about Lilly's Alzheimer's drug; Adcomm votes against...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleAmber raises $100M Series A for two-in-one urinary incontinence treatment
Amber Therapeutics completed its $100 million Series A raise to support its implantable therapy for mixed urinary incontinence through a registrational trial in 2026. The proceeds should give Amber a...
View ArticleGSK wins expanded FDA approval for RSV shot in at-risk adults ages 50 to 59
The FDA on Friday expanded GSK’s RSV vaccine to people ages 50 to 59 who are at an increased risk of the virus, marking another win for the blockbuster shot. GSK’s Arexvy, which was first approved in...
View ArticleModerna’s Covid-19 and flu combo vaccine succeeds in Phase 3 study
Moderna’s Covid-19 and influenza combination vaccine was comparable to shots separately marketed for the two infections in a Phase 3 trial, the company announced Monday morning. Plans are underway to...
View ArticleGSK nixes SpringWorks licensing deal focused on Blenrep-Ogsiveo for blood cancer
GSK is walking away from an expanded partnership deal with SpringWorks Therapeutics, winding down further research activities that would combine Blenrep and Ogsiveo. The UK pharma sent SpringWorks a...
View ArticleAlumis files for IPO ahead of Phase 3 studies for second-generation TYK2...
Precision immunology startup Alumis has filed to go public, pitching itself to Wall Street just three months after raising $259 million from private investors. Alumis didn’t include an estimated figure...
View ArticleShionogi inks deal for preclinical hearing loss therapies; Alvotech’s...
Shionogi licenses hearing loss treatments in deal up to €400M: The Japan-based pharma company paid Cilcare €15 million ($16.1 million) upfront for the option to license two preclinical hearing loss...
View ArticleSkye's stock sinks following eye disease failure as company shifts focus to...
Skye Bioscience is abandoning its entire eye disease pipeline following a Phase 2a trial failure, and it’s pivoting to one of the hottest categories in the industry — obesity. The San Diego-based...
View ArticleOculis touts Phase 2 results in dry eye disease, but most data aren't...
Oculis teased that its dry eye disease therapy worked in a mid-stage trial, but it stopped short of reporting statistically significant data across most endpoints. The ophthalmology biotech identified...
View ArticleEU launches two advice pilots for clinical trial applications as part of R&D...
The EU has initiated two pilot programs aimed at boosting the quality of clinical trial applications amid a broader effort to better integrate clinical research into the European health system. The two...
View Article